Published in Apoptosis on December 01, 2001
Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer (2009) 5.89
Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell (2006) 1.72
The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer (2009) 1.71
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res (2006) 1.58
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res (2006) 1.35
Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc Natl Acad Sci U S A (2007) 1.25
Cancer research meets evolutionary biology. Evol Appl (2009) 1.24
The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res (2008) 1.23
Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol Cancer (2010) 1.11
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell (2013) 1.09
An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol (2011) 1.08
The TRAIL to targeted therapy of breast cancer. Adv Cancer Res (2009) 1.08
Proteome-scale Binary Interactomics in Human Cells. Mol Cell Proteomics (2016) 1.07
Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer. PLoS One (2013) 1.03
Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro Oncol (2010) 1.02
Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene (2012) 1.01
Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression. PLoS One (2010) 0.99
Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol (2014) 0.97
Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Res (2010) 0.96
Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3β/β-catenin signaling pathway. PLoS One (2011) 0.96
The influence of tamoxifen on normal mouse mammary gland homeostasis. Breast Cancer Res (2014) 0.95
The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells. Am J Pathol (2003) 0.95
Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS One (2012) 0.94
Live or let die: oestrogen regulation of survival signalling in endocrine response. Breast Cancer Res (2007) 0.92
Fas binding to calmodulin regulates apoptosis in osteoclasts. J Biol Chem (2005) 0.92
p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy. Breast Cancer Res (2006) 0.92
miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget (2014) 0.92
Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res (2009) 0.90
Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide. Nat Commun (2015) 0.90
Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells. BMC Cancer (2013) 0.90
Fucoidan extract enhances the anti-cancer activity of chemotherapeutic agents in MDA-MB-231 and MCF-7 breast cancer cells. Mar Drugs (2013) 0.90
Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis. PLoS One (2013) 0.89
4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res (2013) 0.89
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer (2003) 0.88
Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med (2013) 0.88
Split-CreERT2: temporal control of DNA recombination mediated by split-Cre protein fragment complementation. PLoS One (2009) 0.86
Activation of c-Jun N-terminal kinase 1 and caspase 3 in the tamoxifen-induced apoptosis of rat glioma cells. J Cancer Res Clin Oncol (2004) 0.85
Progesterone and related compounds in hepatocellular carcinoma: basic and clinical aspects. Biomed Res Int (2013) 0.85
Maspin and MCM2 immunoprofiling in salivary gland carcinomas. Diagn Pathol (2011) 0.85
Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites. FASEB J (2011) 0.85
Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis. Int J Mol Epidemiol Genet (2010) 0.84
Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett (2014) 0.83
Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J Carcinog (2005) 0.83
Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients. Clin Exp Immunol (2004) 0.83
Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells. Anticancer Drugs (2010) 0.83
Tualang honey promotes apoptotic cell death induced by tamoxifen in breast cancer cell lines. Evid Based Complement Alternat Med (2013) 0.82
Regulation of hematopoietic progenitors by estrogens as a basis for new antileukemic strategies. Mol Cell Oncol (2015) 0.82
O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells. PLoS One (2013) 0.82
TARGETING THE GENOTOXIC EFFECTS OF ESTROGENS. Drug Discov Today Dis Mech (2012) 0.82
Integrative Analysis of Response to Tamoxifen Treatment in ER-Positive Breast Cancer Using GWAS Information and Transcription Profiling. Breast Cancer (Auckl) (2012) 0.81
Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells. Chem Res Toxicol (2015) 0.81
Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death. Steroids (2007) 0.81
A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer. Biomed Res Int (2014) 0.81
Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett (2014) 0.80
Synergistic anticancer effects of a bioactive subfraction of Strobilanthes crispus and tamoxifen on MCF-7 and MDA-MB-231 human breast cancer cell lines. BMC Complement Altern Med (2014) 0.80
Modulation of Tamoxifen Cytotoxicity by Caffeic Acid Phenethyl Ester in MCF-7 Breast Cancer Cells. Oxid Med Cell Longev (2015) 0.80
Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Int J Endocrinol (2015) 0.80
Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer (2015) 0.80
Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci (2016) 0.80
Suppression of the death gene BIK is a critical factor for resistance to tamoxifen in MCF-7 breast cancer cells. Int J Oncol (2013) 0.80
Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell line. Oncol Lett (2013) 0.79
Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents. Bioorg Med Chem (2009) 0.79
P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells. Exp Cell Res (2011) 0.79
Cytoplasmic PELP1 and ERRgamma protect human mammary epithelial cells from Tam-induced cell death. PLoS One (2015) 0.79
Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics (2008) 0.78
Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications. Biochim Biophys Acta (2015) 0.78
Spatio-temporal analysis of tamoxifen-induced bystander effects in breast cancer cells using microfluidics. Biomicrofluidics (2012) 0.78
MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy. Mol Cancer (2015) 0.78
Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J Steroid Biochem Mol Biol (2012) 0.78
COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells. Mol Cell Endocrinol (2013) 0.78
A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen. Invest New Drugs (2011) 0.77
B cell and/or autoantibody deficiency do not prevent neuropsychiatric disease in murine systemic lupus erythematosus. J Neuroinflammation (2016) 0.77
Soy promotes juvenile granulosa cell tumor development in mice and in the human granulosa cell tumor-derived COV434 cell line. Biol Reprod (2014) 0.77
New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. BMC Cell Biol (2008) 0.76
A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells. PLoS One (2016) 0.76
RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes. Anticancer Drugs (2016) 0.76
Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen. J Cell Mol Med (2013) 0.76
Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer. Oncotarget (2015) 0.76
Diffusion weighted imaging evaluated the early therapy effect of tamoxifen in an MNU-induced mammary cancer rat model. PLoS One (2013) 0.75
Potential anti-genotoxic effect of sodium butyrate to modulate induction of DNA damage by tamoxifen citrate in rat bone marrow cells. Cytotechnology (2016) 0.75
Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades. J Neuropathol Exp Neurol (2014) 0.75
Radiosensitization of human glioma cells by tamoxifen is associated with the inhibition of PKC-ι activity in vitro. Oncol Lett (2015) 0.75
Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines. BMC Cancer (2015) 0.75
Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche. Endocr Relat Cancer (2016) 0.75
Tamoxifen Action in ER-Negative Breast Cancer. Sign Transduct Insights (2016) 0.75
Repurposing ospemifene for potentiating an antigen-specific immune response. Menopause (2016) 0.75
Interaction of tamoxifen and noise-induced damage to the cochlea. Hear Res (2011) 0.75
Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. BMC Cancer (2017) 0.75
Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J Biol Chem (2000) 1.90
p59fyn tyrosine kinase associates with multiple T-cell receptor subunits through its unique amino-terminal domain. Mol Cell Biol (1992) 1.87
Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J Biol Chem (1999) 1.38
A tyrosine-phosphorylated 70-kDa protein binds a photoaffinity analogue of ATP and associates with both the zeta chain and CD3 components of the activated T cell antigen receptor. J Biol Chem (1992) 1.35
Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res (2000) 1.31
Chemopreventive isothiocyanates induce apoptosis and caspase-3-like protease activity. Cancer Res (1998) 1.27
Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res (2000) 1.27
p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem (2000) 1.19
Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene (1999) 1.17
Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem (1998) 1.10
Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol (2001) 1.01
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res (2000) 0.97
Induction of apoptosis and activation of interleukin 1beta-converting enzyme/Ced-3 protease (caspase-3) and c-Jun NH2-terminal kinase 1 by benzo(a)pyrene. Cancer Res (1998) 0.95
Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res (2000) 0.92
Activation of p38 and c-Jun N-terminal kinase pathways and induction of apoptosis by chelerythrine do not require inhibition of protein kinase C. J Biol Chem (2000) 0.92
Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated phase II enzyme gene expression. Carcinogenesis (1997) 0.89
The nuclear cofactor RAC3/AIB1/SRC-3 enhances Nrf2 signaling by interacting with transactivation domains. Oncogene (2012) 0.87
Activation of signal transduction kinases by tamoxifen. Pharm Res (1997) 0.86
Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Cancer Lett (1996) 0.84
Quinacrine induces cytochrome c-dependent apoptotic signaling in human cervical carcinoma cells. Arch Pharm Res (2001) 0.82
Molecular mechanisms of butylated hydroxylanisole-induced toxicity: induction of apoptosis through direct release of cytochrome c. Mol Pharmacol (2000) 0.81
Phenethyl isothiocyanate, a natural chemopreventive agent, activates c-Jun N-terminal kinase 1. Cancer Res (1996) 0.81
Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver. Biochem Pharmacol (1996) 0.77
Transcription regulation of rat glutathione S-transferase Ya subunit gene expression by chemopreventive agents. Pharm Res (1996) 0.76
Differential induction of UDP-glucuronosyltransferase activity and gene expression in rat liver. Pharm Res (1995) 0.76
Pharmacokinetics of methylprednisolone hemisuccinate and methylprednisolone in chronic liver disease. J Clin Pharmacol (1993) 0.76
cDNA cloning of the mouse bilirubin/phenol family of UDP-glucuronosyltransferase (mUGTbr2-like). Pharm Res (1997) 0.75
Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama. Pharmacogenetics (1991) 0.75